Jon Walsh, founder, chief scientific officer, Unlearn, explains how regulators are clarifying best practices for integrating AI and digital twins into clinical research.

Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma ...

QNRX READ THE FULL QNRX RESEARCH REPORT FDA clears initiation of 2nd NS pivotal whole body clinical study for QRX003, CL-QRX003-002 Quoin Pharmaceuticals (NASDAQ:QNRX) reported 2Q25 results today and ...

The US Food and Drug Administration (FDA) recently announced the availability of the first-ever centralized database of Complete Response ...

LONDON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its ...

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

Pegozafermin, ETNB's FGF21 analog, shows promise in late-stage trials for MASH & severe hypertriglyceridemia. Key data & ...

STATEN ISLAND, N.Y., Aug. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics ...

Vonaprument Selected by EMA as One of ~20 PRIME Development Programs in the Pilot Vonaprument Has the Potential to Be the First Treatment Approved in Europe and the U.S. for Dry AMD with Geographic ...

Market to Reach $430 Million by 2032, Driven by Breakthrough Clinical Trials and Expanding Indications. The global RNA-Based Therape ...

KT-3283, a dual PARP-HDAC inhibitor, to serve as first development program in NanoPalm’s strategic expansion into the ...

Hemispherian's GLIX1 gains FDA approval for glioblastoma trials, promising a novel therapy targeting DNA repair in tumor ...